SCHEMBL7512016

SCHEMBL7512016

OCCCOCC1CCNCC1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TDP1 Q9NUW8 1/20 0.36
GBA1 P04062 4/20 0.35
SLC6A4 P31645 3/20 0.35
UGCG Q16739 2/20 0.35
GBA2 Q9HCG7 2/20 0.35
SLC6A2 P23975 2/20 0.34
HTR3A P46098 1/20 0.34
KCNH2 Q12809 1/20 0.34
CHRM2 P08172 2/20 0.33
CHRM1 P11229 2/20 0.33
CHRM3 P20309 2/20 0.33
GNAI3 P08754 1/20 0.33
GNAO1 P09471 1/20 0.33
GNAI1 P63096 1/20 0.33
EP300 Q09472 2/20 0.33
SLC6A3 Q01959 1/20 0.32
SLC6A1 P30531 2/20 0.31
GABRA5 P31644 2/20 0.31
GABRB2 P47870 2/20 0.31
SLC6A12 P48065 2/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5112018 0.89 SLC6A4 (0.39) TDP1GBA1SLC6A4UGCGGBA2
Hydrochloric Acid SCHEMBL25373369 0.88 TDP1 (0.40) TDP1GBA1SLC6A4UGCGGBA2
SCHEMBL4603376 0.84
SCHEMBL20071877 0.80 TDP1 (0.39) TDP1GBA1SLC6A4SLC6A2HTR3A
SCHEMBL20109731 0.80 MEN1 (0.39) GBA1UGCGGBA2TSHR
SCHEMBL16640337 0.80 GBA1 (0.44) GBA1UGCGGBA2TSHR
SCHEMBL14395367 0.79 SMN1; SMN2 (0.48) TDP1SLC6A4SLC6A2HTR3AKCNH2
SCHEMBL27119127 0.78 TDP1 (0.38) TDP1GBA1SLC6A4SLC6A2HTR3A
SCHEMBL13096717 0.78 TSHR (0.41) TDP1GBA1UGCGGBA2TSHR
SCHEMBL7518042 0.78 TDP1 (0.42) TDP1SLC6A4SLC6A2HTR3AKCNH2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6455548-B2 FOR PROPHYLAXIS AND THERAPY OF ASTHMA, ALLERGIC RHINITIS, DERMATITIS, CONJUNCTIVITIS, ATHEROSCLEROSIS OR RHEUMATOID ARTHRITIS, INFECTION BY HIV, DELAYING OF THE ONSET OF AIDS MERCK & CO., INC. 2002-09-24 US disclosed
US-20020013348-A1 4-alkyl piperidinyl pyrrolidine modulators of chemokine receptor activity MERCK SHARP & DOHME CORP. 2002-01-31 US disclosed
WO-2001064216-A1 4-ALKYL PIPERIDINYL PYRROLIDINE MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY MERCK & CO., INC. (US) 2001-09-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020013348-A1 4-alkyl piperidinyl pyrrolidine modulators of chemokine receptor activity CCR1, CCR4, CCR3 TDP1 4063/4885GBA1 4201/4885SLC6A4 2860/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.